

B. DIVISION OF RESEARCH, ACADEMICS & CANCER CONTROL

RESEARCH ADVISORY BOARD

It is the apex body for research activities in this institute. The RAB meetings are meant to be held periodically to assess the quality of Research work undertaken in the institute. The RAB members represent important scientific research organizations, governmental and nongovernmental institutes. This year's RAB meeting was last held on 13-11-2024. The discussions in the RAB meeting were divided into Basic Science, Epidemiology and Clinical Research. The research work undertaken and the publications coming out there of were presented to the members, the impacts of the researcher were discussed and future directives were outlined.

INSTITUTIONAL RESEARCH COMMITTEE

The Research Subcommittee has been reconstituted and renamed as Institutional Research Committee (IRC) in keeping with the requirement with NBE (National Board of Exam). There has been an addition to the committee. A fresh SOP has been prepared

INSTITUTIONAL ETHICS COMMITTEE

Institutional Ethics Committee (IEC) was reconstituted on the advice of the Governing Body/ Managing Committee of SGCCRI, Thakurpukur, in January 2011.

An SOP for the Institutional Ethics Committee (IEC) was drafted in the first meeting of the committee, in keeping with the ICMR (Indian Council of Medical Research) and Good Clinical Practice (GCP) guidelines. The SOP was further revised in March 2013 (ver1.1) and May 2014 (ver 1.2). October 2015 (Vol 1.3), and May 2014 (ver 1.2) March 2017 (Vol1.4) August 2023 (SOP 02 Ver 1)

In the meeting of IEC on 16th March 2013, it was unanimously decided that the IEC would have to be affiliated to CDSCO in keeping with the advice from the Drug Controller General of India under Ministry of Health and Family Welfare, Govt of India. The IEC of SGCCRI was granted approval by the CDSCO on 22nd April 2013.

As per Government guidelines IEC is accredited with **CDSCO**, Drug Controller General of India, Govt. of India. And the **registration** is valid till **26th July 2030**. and Government of India Ministry of Health & Family Welfare **Department of Health Research** till **5th October 2028**

There are 12 members on this reconstituted committee at present. In the year 2023 there was 3 IEC meetings (10-2-2023, 05-05-2023, 1-12-2023) a total of 15 studies were presented out of which 4 were of DNB students. This year (2025) there was three IEC meetings (07-03-2025,

22-8-25 and 07-11-2025)a total of 12 studies were discussed and passed. Five of these studies were DNB/DrNB thesis projects.

The Division of Research consists of:

Academic Section:

Records Section


Molecular Biology section

Epidemiological Research section

Clinical Studies Division

The Research Sub-Committee, composed of research-oriented persons of this institute, discuss on the merits and demerits of proposed studies, and make recommendations to the Institute Ethics Committee. The Research Advisory Board, composed of eminent personalities (from major institutes in India) in different fields of cancer research, is the guiding body of the Research activities of this institute

COMPOSITION



- | | | |
|------------------------------|---|---------------------------------------|
| Fenella S. Anthony (D’Cruz) | - | Office Coordinator Research |
| Jagriti Karmakar | - | Clinical Trial Coordinator |
| Sambhu Das | - | Assistant |
| Chanchal Sarkar | - | Assistant |
| Debashish Banerjee | - | Junior Officer Statistics and Records |

Clinical Trial Division

The Clinical Trial Division was established to address matters related to regulatory drug trials. Its primary responsibility is to ensure that the hospital site adheres to the guidelines set by the Drug Controller General of India (DCGI). This includes registering the site and Principal Investigators with the DCGI, as well as ensuring that all research personnel and Principal Investigators are trained in Good Clinical Practice (GCP), the fundamentals of clinical research, research ethics, research management, quality assurance, and data management within the context of clinical research.

Outline of Activities In Different Sections of Research Divisions/ Activities

In this institute, the Division of Research, academic affairs, and cancer control programs are amalgamated together. The broad subdivisions are as follows:

RESEARCH ACTIVITIES

Activities on cancer epidemiology & cancer registry

Development of an Atlas of Cancer in India (NCRP, ICMR)

Population-Based Cancer Registry (PBCR), Kolkata

Activities of Special Cell for PBCRs of NE India.

Hospital-based Cancer Registry.

Research Grant: Rs. 5, 50,000/-

Activities under clinical studies In in-house – investigator initiated trials, DNB /DrNB thesis, PhD thesis with IICB, Calcutta University, IIT Kharagpur

Multicentric Studies – involving other cancer centers and Basic science institutes.

Case Control Studies with Breast Cancer with CFI

Evaluation of degree of association of various parameters in Breast Cancer with CNCI

Indian Breast Cancer Genome Atlas: A pan India: Research to undertake omics based molecular & clinical analysis of 1000 Indian Breast Cancer patients.

Basic and Molecular Research on Cancer

Basic and Translational Research Division

The Basic Research and Molecular Biology division of Saroj Gupta Cancer Centre and Research Institute, largely, deals with Genetics, Genomics, Epidemiology, Immunology, and Cell and Molecular Biology of Cancer. We are developing a translational research program in the broad subject area of cancer. Emphasis has been placed on the participation of clinical and basic scientists in the research programs. Research projects with specific clinical questions are being addressed using advanced research tools and techniques. Also, collaborative research programs with different research institutions and universities have been initiated. Funding for the research activities is being made through extramural and intramural funds. Along with the advanced research in cancer biology, this division is also actively involved in molecular diagnostic tests for affected patients.

Highlights of recent achievements

Dr. Stuti Roy, enrolled in SGCC&RI for her doctoral program, has been awarded her PhD degree from Calcutta University. She is the **first PhD student** from the **SGCC&RI** under the guidance of Dr. Somsubhra Nath.

Dr. Suryendu Saha, enrolled in SGCC&RI for his doctoral program from the University of Calcutta, has defended his PhD thesis in the process of completion. He is the **second PhD student** from the **SGCC&RI** under the guidance of Dr. Somsubhra Nath.

Prof. Sharmila Sengupta has been selected as the prestigious ICMR-Emeritus Scientist from the SGCC&RI for her contribution to cancer biology.

Dr. Koushik Mondal has received two ICMR grants (Small and Intermediate) as Co-PI.

Mr. Ratnadeep Paul has been promoted to a Senior Research Fellowship from ICMR, Govt. of India

Ms. Anupa Chattopadhyay has been awarded a Senior Research Fellowship from the DST-INSPIRE scheme, Govt. of India.

SGCCRI has become a member of the Indian Cancer Genome Atlas (ICGA) Project: Dr Susanta Roychoudhury (Founding Member), Dr Samir Bhattacharyya (Institutional Principal Investigator), and Dr. Koushik Mondal (Point of Contact). The project is progressing well with sufficient contributions from the Clinicians and Scientists of SGCC&RI.

SGCCRI is also a member of the Global Cancer Consortium (GCC) and members of the Molecular and Translational Research Group, besides being members in an individual capacity, also regularly participate in the academic programs (Lecture series, Conferences, and Workshops) of GCC.

Academic activities:

Post-doctoral training Program

PhD program in Cancer Cell and Molecular Biology (registration from the University of Calcutta/ Jadavpur University/ West Bengal University of Health Science)

Short- and long-term summer training program in Cancer Cell and Molecular Biology

Our team

Research Investigators

1. Prof. Susanta Roychoudhury (PhD, FNA, FASc, FNASc, FASc&T (Advisor)
2. Prof. Sharmila Sengupta (PhD, FNASc., FASc. &T) (Chief, Basic Research)
3. Dr. Koushik Mondal (PhD) (Sr. Scientist)

Lab Members

- Ms. Anupa Chattopadhyay (DST INSPIRE Senior Research Fellow)
- Mrs. Swarnali Saha (Lab Manager)
- Ms. Rajeswari Dutta (Lab Technician)
- Ms. Susmita Mondal (Lab Technician)
- Mr. Soumen Mahapatra (Lab Technician)
- Ms. Sinjini Dutta (Project Associate, ICGA)

Research Trainees (May,2023-August, 2024)

Name	Affiliation	Project title	Guide
Ms. Silpa Dalal (Summer Intern)	M.Sc., Department of Biochemistry, Ballygunge Science College, University of Calcutta, Kolkata	Study of immune-response factors in colorectal adenocarcinoma	Dr. Koushik Mondal
Ms. Dipanjana Mandal (Summer Intern)	M.Sc., Department of Medical Biotechnology & Bioinformatics, JIS Institute of Advanced Studies & Research Centre for Health Science & Technology	Immune and Molecular Profiling of DOCK2 and the CXCL12-CXCR4/CXCR7 Pathway in Rectal Cancer: A Multi-Omics Correlation Study	Dr. Koushik Mondal

Ms. Koyel Chatterjee (Trainee)	M.Sc., Dept. of Biotechnology, MS Ramiah College of Arts, Science, and Commerce. Bangalore City University, Bangalore	Training in Molecular Biology	Prof. Sharmila Sengupta & Dr. Koushik Mondal
Mr. Somdeb Bhattacharyya (Trainee)	M.Sc., Dept. of Zoology, Vivekananda College, University of Calcutta, Kolkata	Validation of a PCR-based detection method for HPV16 diagnosis in cervical biopsy tissue & Exploration of roles of miRNA in cervical cancer pathogenesis”	Prof. Sharmila Sengupta
Ms. Sreyoshi Majumder (Summer Intern)	M.Sc., Department of Genetics, School of Biological Sciences, Madurai Kamaraja University, Madurai, Tamil Nadu.	Validation of a PCR-based detection method for HPV16 diagnostics in cervical biopsy tissues & Characterization of immune infiltration in HPV16 positive PIK3CA mutant and PIK3CA wild type tumours of TCGA-CESC Cohort and Indian Cohort.	Prof. Sharmila Sengupta
Ms. Nayana Monu (Summer Intern)	Final year M.Sc. , Department of Biotechnology, Amity University, Kolkata	Exploring the molecular basis of host pathogen interactions in HPV related cervical cancers among Indian women.	Prof. Sharmila Sengupta
Sudip Bakshi (Summer Research Fellow, National Science Academies with Inspire Fellowship)	Ist year student of M.Sc. Biochemistry, Central University of Punjab.	Molecular Profiling of Human Papilloma Virus (HPV) and its Role in Cervical Lesion Progression among Women in Eastern India cohort	Prof. Sharmila Sengupta

Research grants:

Efficacy of spindle assembly checkpoint among breast cancer subtypes: a crosstalk driven by hormone receptors (DST-INSPIRE fellowship awarded to Mr. Suryendu Saha)

PI: Dr. Somsubhra Nath, **Co-PI:** Prof Susanta Roychoudhury

Duration: 5 yrs (2018-2023); Sanctioned amount: Rs. 19,60,000

Study on relationship between Gain-of-Function mutant P53 and stemness as an underlying cause of chemoresistance in ovarian cancer (DST-Women Scientist A, awarded to Dr. Damayanti Das Ghosh)

PI: Dr. Damayanti Das Ghosh; **Mentor:** Prof. Susanta Roychoudhury
Duration **(2018-2022) 4 yrs;** Sanctioned amount: **Rs. 35,00,000**

Clinical role of a pair of novel mutations in BCR-ABL1 towards therapy switch in Imatinib-resistant chronic myeloid leukemia (Awarded to Dr. Somsubhra Nath by the Lady Tata Memorial Trust)

Duration: **3 years (2022-2024);** Sanctioned amount: **Rs.79,93,360**

Study on the role of tumor suppressor gene TP53 mutations in double strand break repair of type ovarian cancer (DST-INSPIRE fellowship awarded to Ms. Anupa Chattopadhyay)

PI: Prof Susanta Roychoudhury; **Co-PI:** Dr. Damayanti Das Ghosh

Duration: **5 yrs (2021-2026);** Sanctioned amount: **Rs. 20,00,000**

Collaborative Small Research Grant with MAHE, Manipal University

Targeting EZH2 to overcome immunotherapy resistance for the treatment of immunologically cold lung cancer. (Small ICMR Grant has been approved 2025). **Co-PI:** Dr. Koushik Mondal, **PI:** Dr. Manash K Paul

Collaborative Intermediate Research Grant with MAHE, Manipal University

Deciphering lung tumor-stroma crosstalk during tumor progression, using intersectional genetics, spatial transcriptomics, and patient-derived 3D organoid models, and the development of stroma-targeting therapy. (Intermediate ICMR Grant has been approved 2025). **Co-PI:** Dr. Koushik Mondal, **PI:** Dr. Manash K Paul

Building the scientific rationale for proposing potential novel treatment combinations of HPV16 related cervical cancers in Indian women through genomic and translational analyses. (ICMR Emeritus Scientist Project funding).

Future work plan:

Identification of prognostic biomarkers to therapeutic response.

Understanding novel biomarker identification for immunotherapy response.

Development of organoid cultures from ovarian, cervical, gastric, and colorectal cancer.

Creation of tissue repository and repository of patient-derived organoids

Testing the feasibility of implementing liquid biopsy in ovarian and cervical cancers

Molecular Biology -Publications (2021 – 2025):

KRAS mutation subtypes and their association with other driver mutations in oncogenic pathways. **Mondal K***, Posa MK, Shenoy R, Roychoudhury S*. (2024). *Cells*. 13(14), 1221; <https://doi.org/10.3390/cells13141221> (*corresponding author).

Prognostic indicators for precision treatment of non-small cell lung carcinoma. DasGhosh D, McDonald H, Dutta R, Krishnan K, Thilakan J, Paul MK, Arya N, Rao M, Rangnekar VM. (2024). *Cells*. 13(21), 1785.

MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness. Ghatak D, Datta A, Roychowdhury T, Chattopadhyay S, **Roychoudhury S**. *Mol Cancer Res*. 2021 Oct;19(10):1635-1650. doi: 10.1158/1541-7786.MCR-20-0717

Value added by an inter-continental cancer consortium. Rao M, Venkatraman P, Mukhopadhyay D, **Roychoudhury S**, Vanderford NL, Rangnekar VM. *Genes Cancer*. 2021 May 21; 12:65-68. doi: 10.18632/genesandcancer.215. eCollection 2021

S Ghuwalewala, D Ghatak, S Das, S Roy, P Das, M Butti, R Gorain, S Nath, GC Kundu, **S Roychoudhury**. MiRNA-146a/AKT/ β -catenin activation regulates cancer stem cell phenotype in oral squamous cell carcinoma by targeting CD24. *Fronts Oncol* (2021), doi: 10.3389/fonc.2021.651692

S Dey, D Bhattacharyya, P P Gupta, **S Nath**. Long-term Outcome of Philadelphia Chromosome Positive Leukemia from Eastern Indian Sub-continent: An Experience in the Era of Tyrosine Kinase Inhibitor (TKI) Therapy. *Clin Lymphoma Myeloma Leuk* (2021). doi: <https://doi.org/10.1016/j.clml.2021.06.026>

D Sengupta, S Banerjee, P Mukhopadhyay, R Mitra, **T Chaudhuri, A Sarkar, G Bhattacharjee, S Nath, S Rouchoudhury**, S Bhattacharjee, M Sengupta. A comprehensive meta-analysis and a case-control study give insights into genetic susceptibility of lung cancer and subgroups. *Sci Rep*. 2021 Jul 16;11(1):14572. doi: 10.1038/s41598-021-92275-z.

Nath S., Roy S. (2021) Genomic Instability in Carcinogenesis: the role of oxidative stress In: Chakraborti S., Ray B.K., Roychowdhury S. (eds) *Handbook of Oxidative Stress in Cancer: Mechanistic Aspects*. Springer, Singapore. https://doi.org/10.1007/978-981-15-4501-6_155-1

S Saha, S Dey and **S Nath**. Steroid hormone receptors: links with cell cycle machinery and breast cancer progression. *Fronts Oncol*. 2021. Mar 12;11:620214. doi: 10.3389/fonc.2021.620214

Roy S, Saha S, Dhar D, Chakraborty P, Singha Roy K, Mukherjee C, **Gupta A, Bhattacharyya S**, Roy A, Sengupta S, **Roychoudhury S, Nath, S**. Molecular *crossstalk* between CUEDC2 and ER α influences the clinical outcome by regulating mitosis in breast cancer. *Cancer Gene Therapy*. 2022 Jun 22:1-0.

Dey S, Basu S, Shah S, Bhattacharyya D, **Gupta PP**, Acharjee M, Roychoudhury S, **Nath S**. Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study. *Cancer Treatment and Research Communications*. 2022 Jan 1;33:100635.

Mukhopadhyay, Anindya; Roy, Stuti; Saha, Suryendu; Majumder, Satwata; Dey, Samya; Bhattacharyya, Samir¹; Gupta, Arnab¹; Nath, Somsubhra. A Comparative Analysis of Features and Outcome of Breast Cancer in Younger versus Older Women: A Single Centre Experience from Eastern Indian Subcontinent. *Journal of Cancer Research and Therapeutics* 2023; 19(Suppl 1):p S59-S66

Bandopadhyay S, Prasad P, Ray U, **Das Ghosh D**, Roy SS. SIRT6 promotes mitochondrial fission and subsequent cellular invasion in ovarian cancer. *FEBS Open Bio.* 2022 Jun 10. doi: 10.1002/2211-5463.13452. Epub ahead of print. PMID: 35686673.

Ghatak D[‡], **Das Ghosh D[‡], Roychoudhury S.** Cancer Stemness: p53 at the Wheel. *Front Oncol.* 2021;10:604124. doi:10.3389/fonc.2020.604124.[[‡]equal contribution]

Das Ghosh D, Roy Chowdhury R, Roychoudhury S. EPV139/#616 TP53 mutations differentially affect prognosis of endometrial cancer: an in-silico approach. *International Journal of Gynecologic Cancer* 2021;31:A85.

Chakraborty P, Paul R, Chowdhury A, Mukherjee N, **Nath S, Roychoudhury S.** The anaphase promoting complex/cyclosome ubiquitylates histone H2B on the promoter during UbcH10 transactivation. *FEBS Lett.* 2023 Feb;597(3):437-447. doi: 10.1002/1873-3468.14563. Epub 2022 Dec 21. PMID: 36520528.

Saha T, Bhowmick B, Sengupta D, Banerjee S, Mitra R, **Sarkar A, Chaudhuri T, Bhattacharjee G, Nath S, Roychoudhury S,** Sengupta M. No association of the common Asian mitochondrial DNA haplogroups with lung cancer in East Indian population. *J Basic Clin Physiol Pharmacol.* 2022 Mar 28;34(5):663-668. doi: 10.1515/jbcpp-2021-0352. PMID: 35338796.

Sengupta D, Mukhopadhyay P, Banerjee S, Ganguly K, Mascharak P, Mukherjee N, Mitra S, Bhattacharjee S, Mitra R, **Sarkar A, Chaudhuri T, Bhattacharjee G, Nath S, Roychoudhury S,** Sengupta M. Identifying polymorphic cis-regulatory variants as risk markers for lung carcinogenesis and chemotherapy responses in tobacco smokers from eastern India. *Sci Rep.* 2023 Mar 10;13(1):4019. doi: 10.1038/s41598-023-30962-9. PMID: 36899086; PMCID: PMC10006236.

Ghosh D, Pakhira S, **Das Ghosh D, Roychoudhury S,** Roy SS. Ets1 facilitates EMT/invasion through Drp1-mediated mitochondrial fragmentation in ovarian cancer. *iScience.* 2023 Aug 2;26(9):107537. doi: 10.1016/j.isci.2023.107537. PMID: 37664613; PMCID: PMC10469980.

Das Ghosh D*, Roy Chowdhury R, Dutta R, Mukhopadhyay I, Mukhopadhyay A, **Roychoudhury S.** In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries. *Gynecol Oncol Rep.* 2023 May 26;47:101209. doi: 10.1016/j.gore.2023.101209. PMID: 37293351; PMCID: PMC10245003.

[*corresponding author]

Ghosh A, Ghosh A', Sinha A, Mathai S, Bhaumik J, Mukhopadhyay A, Maitra A, Biswas NK, Majumder PP and **Sengupta S** (2023). Identification of HPV16 positive cervical cancer subsets characterized by divergent immune and oncogenic phenotypes with potential implications for immunotherapy. **Tumor Biology** 45: 55-69.

Nath S, Sarkar M, Maddheshiya A, De D, Paul S, Dey S, Pal K, Roy SK, Ghosh A, **Sengupta S**, Paine SK, Biswas NK, Basu A, Mukherjee S. Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups (2023). **Microbiol Spectr.**,11(6):e0236823. doi:10.1128/spectrum.02368-23.

Sinha A, Ghosh A, Ghosh A', Mathai S, Bhaumik J, Mukhopadhyay A, Maitra A, Biswas NK, and **Sengupta S** (2024). MAL expression downregulation through suppressive H3K27me3 marks at the promoter in HPV16 related cervical cancer is prognostically relevant and manifested by the interplay of novel MAL antisense long noncoding RNA AC103563.8, E7 oncoprotein and EZH2. **Clinical Epigenetics** 16:40.

Sinha A, Ghosh S, Ghosh A, Ghosh A', Mathai S, Bhaumik J, Mukhopadhyay A, Maitra A, Biswas NK, and **Sengupta S** (2024). Unfurling the functional association between long intergenic noncoding RNAs (lincRNAs) and HPV16-related cervical cancer pathogenesis through weighted gene co-expression network analysis of differentially expressed lincRNAs and coding genes. **Carcinogenesis** bgae019, <https://doi.org/10.1093/carcin/bgae019>.

Ghosh A, Sinha A, Ghosh A', Roy S, Mallick S, Kumar V, Mathai S, Bhaumik J, Mukhopadhyay A, Sen S, Chandra A, Maitra A, Biswas NK, Majumder PP and **Sengupta S**. (2024). Biological and clinical relevance of correlated co-expression of coding and noncoding RNAs in cervical cancers. **Human Genomics** 18 (1): 91.

Bhattacharya A, Chakraborty K, Saha P, Saha S, Roychaudhuri P, Baidya JL, Ghosh A, Chakraborty D, **Sengupta, S***, Sil SK* (2024). Cervical cytology abnormalities and associated genotype patterns of High-Risk HPV Infection in Women of Tripura, North-East India: A Hospital-Based Study. **American Journal of Epidemiology**, kwae364, <https://doi.org/10.1093/aje/kwae364> (*co-Corresponding Authors).

Recognition:

The Department of Scientific & Industrial Research (DSIR), Government of India recognizes this Institute as a “**Scientific & Industrial Research organization (SIRO)**”. As a result of this recognition,

donation to the scientific activities of this Institute qualifies for exemption u/s 35(i)(ii) of Income Tax Act, 1961.

SGCCRI is a member of **Star Alliance of National Institute of Biomedical Genomics (NIBMG), Kalyani** – an Institute under Division of Biotechnology, Govt of India.

SGCCRI has an **MOU with IICB** (Indian Institute of Chemical Biology) for active collaborative Research.

The Institutional Ethics Committee of SGCCRI is registered with the **CDSCO**, Drug Controller General of India, Govt. of India and the **registration** is valid till **26th July 2030** and Government of India Ministry of Health & Family Welfare **Department of Health Research** till **5th October 2028**

SGCCRI has signed **MOU with Swasthya Niketan Integrated Healthcare and Research Organization** for active collaborative Research and Clinical Studies.

This institute is an accredited member of the **National Cancer Grid (NCG)**, an umbrella organization of all the major cancer centres in India, under the aegis of the Atomic Energy Commission, Govt of India. The purpose of NCG is collaborative research, development of guidelines suitable for Indian patients, and better teaching facilities. This institute is a very active member of it. Electronic Medical Record (EMR) is being introduced in the SGCCRI with the active support of the NCG.

Collaborating Institute	PI	Co-PI/collaborators from SGCCRI/ other Institutes	Project keywords
University of Calcutta	Dr. Mainak Sengupta (HOD, Dept. of Genetics, CU)	Prof. S Roychoudhury, Dr. S Nath, Dr.Goutam Bhattacharjee	Lungcancer/Tobacco smoke/Xenobiotic metabolism/DNA repair/Polymorphism

National Institute of Bio-Medical Genomics (NIBMG)	Prof.Sharmila Sengupta	Prof. S Roychoudhury, Dr. R Roy Chowdhury, Dr. N R Mondal , Prof. Arindam Maitra (NIBMG)	Cervical cancer/ HPV-16/ E7
In-House	Dr. Sharmila Sengupta Dr. Damayanti Das Ghosh	Prof. S Roychoudhury, Dr. R Roy Chowdhury, Dr. N R Mondal	Cervical cancer organoid development
National Institute of Bio-Medical Genomics(NIBMG)	Prof Analabha Basu (NIBMG)	Prof .Sharmila Sengupta	HPV-16 persistence in the Kalyani Cohort using a longitudinal approach.
Presidency University	Dr. Susmita Mondal (Assistant Professor, Dept of Life Sc)	Dr. Koushik Das	Prostate Cancer, Glucose metabolism, PTEN
Kolkata Gynecological Oncology Trials and Translational Research Group (KolGO Trg)	Dr. Damayanti Das Ghosh, Dr.R Roy Chowdhury	Dr. Damayanti Das Ghosh, Prof. S Roychoudhury, Dr. R Roy Chowdhury, Dr. Asima Mukhopadhyay (KolGO Trg)	Finding cross-talk between POLE and TP53 mutations in endometrial cancer
Kolgotrg/NIPER	Dr. Damayanti Das Ghosh	Prof. S Roychoudhury, Dr. Sandipan Chowdhuri Dr.Asima Mukhopadhyay (KolGO Trg) Dr. Dipanjan Ghosh (NIPER)	Deciphering the interplay of TP53 mutational variation and homologous recombination deficiency in therapeutic response to platinum and PARP inhibitor in ovarian cancer
NIT Durgapur	Prof. Asish Mukhopadhyay (NIT Durgapur)	Dr. Damayanti Das Ghosh, Prof. S Roychoudhury,	Developing a machine learning based platform for defining drug sensitivity biomarkers for screening of novel lung-cancer drug using patient derived organoid model”

Manipal Academy of Higher Education (MAHE), Manipal (endeavor of Indo-US based Global Cancer Consortium (GCC))	Dr. Damayanti Das Ghosh Dr. Rama Rao Damerla (MAHE)	Prof. S Roychoudhury, Prof. Mahadev Rao	Interplay of TP53 mutation and codon72 polymorphism in prognosis of TP53 mutated gynecological cancers
CSIR-Indian Institute of Chemical Biology (IICB)	Dr. Damayanti Das Ghosh	Prof. S Roychoudhury, Dr. Sandipan Chowdhuri Dr. Shilpak Chatterjee (IICB), Dr. R Roy Chowdhury	Search of prognostic cues for epithelial ovarian cancer from liquid biopsy based cell-free DNA, circulating tumor cells and T cell receptors
National Institutes of Pharmaceutical Education and Research (NIPER), Kolkata	Dr. Damayanti Das Ghosh	Prof. S Roychoudhury Dr. Dipanjan Ghosh (NIPER)	Development of isogenic ovarian cancer cell lines with different TP53 hot-spot mutations to study their effects on DNA repair and test differences in drug response. Establishment of 3D culture model of ovarian cancer from patient-derived tissue to test novel drug molecules.
Institute of Genomics and Integrative Biology (CSIR-IGIB)	Prof. Shantanu Chowdhury (CSIR-IGIB) Dr. Samir Bhattacharyya	PI: Dr. Samir Bhattacharyya Co PI : Dr. Sudipto Roy Point of contact: Dr. Koushik Mondal	The Indian Breast Cancer Genome Atlas (ICGA). This is a prestigious Research endeavor of Govt. of India, inspired by the famous and immensely

			<p>popular International cancer research project named 'The Cancer Genome Atlas' (TCGA)</p> <p>Present status: first data release in September, 2023</p>
--	--	--	---

National Board of Examinations (NBE) recognizes this Institute for training in Radiation Therapy and Surgical Oncology.

DNB (Surgical Oncology – Super Specialty): This centre is one of the 1st few centres in India to start this course in 2005. Previously there were two seats for this course. From 2021 the seat number has been upgraded to 4 seats per year. Accordingly four new students were admitted to the course this year. 4 students are admitted to the course each year Dr Indrajit Malik, Dr Azam Ali Shaik, Dr Pratap Kumar Deb and Dr Pranjit kalita has completed their tenure. Dr Vishal Mukherjee and Dr Radha Raman Mondal has passed. . In the academic session 2023 following candidates joined our institute as DrNB trainee (Dr Namrata Mazumdar, Dr Prasant Kr Sinha, Dr Subrato Mahakur, Dr Siddharth . In the academic session 2024, following candidates joined our institute as DrNB trainee Dr. Jaydeep Mandal, Dr. Himen Baidya, Dr. Bajrang Sharma and Dr, Rupali Niraj.

DNB (Radiotherapy – Specialty): Previously One seat was allotted for this course. From the year 2021 the seat number has been upgraded to two. As such Two students have been admitted to the course this year.(Dr Sourav Banerjee and Dr Tarun.) Dr Sourav Banerjee has passed. At present our institute accredited with NBEMS 1 (Post MBBS) + 1 (Post Diploma) seats in the speciality of Radiation Oncology. Dr Sourav Banerjee and Dr Tarun S has passed this year.

Paramedical Courses

This Institute conducts 2-years + 6 months internship diploma courses in Paramedical sciences recognized by the State Medical Faculty of West Bengal (SMFWB). We conduct the following 4 courses:

- Diploma in Laboratory Technology (DMLT-Tech)
- Diploma in Radiography (DRD –Tech)
- Diploma in Radiation Therapy Technology (DRT –Tech)
- Diploma in Operation Theatre Technology (DOTT)

Other Academic Activities:

CME Programme: weekly on every Thursday. Guest faculties (local, national, and international) and in-house faculties take part in different cancer-related issues. This calendar year we have conducted 50 CME programmes.

Publication of Scientific Bulletin: As in other years the academic Scientific Bulletin was published this year also under the editorship of Dr. Samir Bhattacharyya and Dr. Arnab Gupta

Activities regarding holding scientific conferences/seminars/Palliative Care courses.

WHAT'S NEW

Dr. Pratap Deb presented his paper in a prestigious conference in UK and was one of the winners of Oncology Fellowships offered by the Indian Association of Surgical Oncology 2024.

CLINICAL STUDIES DIVISION

INTRODUCTION:

Dr Rahul Roy Chowdhury brings extensive expertise in clinical research, ensuring that all trials adhere to rigorous ethical and procedural standards. Under his leadership, the division has continued to expand its portfolio of clinical studies, the Clinical Studies Division at Saroj Gupta Cancer Centre & Research Institute, established in 2012, has since played a pivotal role in advancing cancer research through its participation in numerous clinical trials. Over the years, the division has successfully completed a variety of commercial clinical trials, both national and international, contributing significantly to the development of cutting-edge treatments. In addition to industry-sponsored trials, the site is also actively involved in investigator-initiated studies, further demonstrating its commitment to academic and translational research.

This prestigious site is accredited by the Cervix Cancer Research Network (CCRN), under the Gynecologic Cancer Intergroup (GCIg), a global consortium of cancer centres dedicated to improving treatment outcomes for women with gynecologic cancers. This recognition underscores the division's high standards of clinical research and its contributions to the global fight against cancer, particularly in the realm of gynecological oncology. Leading the division is Dr. Rahul Roy Chowdhury, a highly respected Gynecological Oncologist and Clinical Trial Administrator of the Institute. As a GCP-certified Principal Investigator, Dr. contributing to advancements in cancer care.

Supporting this work is a dedicated and experienced full-time Clinical Research Coordinator, who ensures the smooth and efficient conduct of all clinical research activities. This role is critical in maintaining compliance with regulatory requirements and timelines, fostering a research environment where innovation and patient care intersect seamlessly.

Together, the team at the Clinical Studies Division at Saroj Gupta Cancer Centre & Research Institute is at the forefront of clinical research, dedicated to improving cancer treatment outcomes and contributing to global scientific knowledge.

PAST AND ONGOING CLINICAL TRIALS:

SL.No	Study Title	Principal Investigator	Current status
1	A Multi-Center, Single Arm, Phase IV Study to Assess the Safety and Efficacy of Lenvatinib Capsules for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer OR for the First Line Treatment of Patients with Unresectable Hepatocellular Carcinoma.	Dr. Rakesh Roy	Ongoing
2	SPEAR-(Study of PIK3CA mutations and Effectiveness and tolerability outcomes of Alpelisib in Real – world) A descriptive study of PIK3CA mutations and outcomes with Alpelisib in patients with HR- positive and HER2- negative advanced breast cancer(ABC)/metastatic breast cancer(MBC) in India	Dr Rakesh Roy	Closed
3	A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer (INTERLACE)	Dr.Rahul Roy Chowdhury	Recruitment closed, Follow up on
4	SENTICOL III - International Validation study of Sentinel node Biopsy in Early Cervical Cancer	Dr.Rahul RoyChowdhury	Open to recruitment
5	Intermittent PARP Inhibitor Regimen for Ovarian Cancer (IPIROC)	Dr.Rahul RoyChowdhury	Open.to recruitment
6	A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY)	Dr.Rakesh Roy	Open.to recruitment

CME Program

Since, March 2006, this institute is organizing CME programs regularly on every Thursday for the benefit of Faculty and DNB trainees. Apart from in-house faculty members, several guest speakers have delivered lectures on various topics on advanced oncology. The following table gives the number of such CMEs since its inception.

Period	No of CMEs
March 2006	5
April 2006-March 2007	46
April 2007 – March 2008	48
April 2008 – March 2009	43
April 2009- March 2010	43
April 2010 – March 2011	45
April 2011 – March 2012	49
April 2012 – March 2013	49
April 2013 – March 2014	46
April 2014 – March 2015	46
April 2015 – March 2016	49
April 2016 – March 2017	48
April 2017-March 2018	48
April 2018-March 2019	49
April 2019-March 2020	47
April 2020- March 2021	19
April 2021- March 2022	50
April 2022- March 2023	49
April 2023- March 2024	48
April 2024- March 2025	48

WEEKLY CME (December 2024- NOVEMBER 2025)

12/12/2024	Topic: Breast Cancer talk .	Speaker: Dr. Indranil Ghosh (Medical Oncologist, Apollo Hospital, Kolkata)
19/12/2024	Topic: Day to Challenges faced by the medical fraternity.	Speaker: Dr. Vidya Shetty (Medico Legal Expert)
26/12/2024	Topic: Challenging Cases in Pediatric Lymphoma/ Leukaemia	Speaker: Dr. Arnab Gupta
02/01/2025	Topic: Borderline Ovarian Tumor	Speaker: Dr. N.R. Mondal
09/01/2025	Topic: Optimizing treatment outcomes in unfit AML patients with BCL2 inhibition.	Speaker : Dr. Anupam Chakrapani (Senior Consultant & Head, Dept. of Clinical Hematology & BMT, Apollo Gleneagle Hospital, Kolkata)
16/01/2025	Topic: “ Malignant Pleural Effusion and Ascites”.	Speaker: Dr. Sumit Sharma (Lead Consultant Imaging and Interventions, HCG Cancer Centre, New Town, Kolkata, WB) .
23/01/2025	Topic: NABH SESSION	Speaker: Dr. Abhimanyu Bishnu
30/01/2025	Topic :PPTID a Case Report	Speaker : Dr. Sampuran Acharya
06/02/2025	Topic: Molecular Updates in Endometrial Cancer.	Speaker: Dr. Nihanthy Sreenath
13/02/2025	Topic: Modern Radiation therapy modalities in Lymphoma.	Speaker: Dr. Arundhati Mondal
20/02/2025	Topic: Automated analysis of methylated gene markers for early detection of Breast, Cervical, & Prostate Cancer.	Speaker: Dr. Saraswati Sukumar
27/02/2025	Topic: Pediatric medulloblastoma	Speaker: Dr. Arnab Chakraborty
06/03/2025	Topic: Pathophysiological interaction between chronic constipation & systemic co morbidities & its management.	Speaker: Dr. Debasish Roy

13/03/2025	Topic: Role of RT in Oncological Emergencies.	Speaker: Dr. S. Tarun
20/03/2025	Topic: NABH	Speaker : Dr. Abhimanyu Bishnu Dr. Sumanta Dasgupta Dr. Subhamoy Paul
27/03/2025	Topic: NABH	Speaker : Dr. Sumanta Dasgupta
03/04/2025	Topic: NABH: Clinical Audit	
17/04/2025	Topic: CPC- Dept of Pathology	Speaker: Dr. Soumendra Mishra Dr. Sunipa Ghosh
24/04/2025	Topic: Interesting Case of ITS	Speaker: Dr. Soma De
08/05/2025	Topic: Two interesting Cases of Pathology.	Speaker: Dr. Soumendra Mishra
15/05/2025	Topic: Interstitial brachytherapy in Gynaecological malignancies and Our Hospital experience.	Speaker: Dr. Arundhati Mondal
22/05/2025	Topic: Tumor Immunology	Speaker: Dr. Nihanthy Sreenath
29/05/2025	Topic: Application of NGS technology in Solid Tumors.	Speaker: Dr. Aparna Natarajan
05/06/2025	Topic: Optimizing treatment in recurrent /metastatic Squamous Cell Carcinoma.	Speaker: Dr. Rakesh Roy
12/06/2025	Topic: Recent Updates of pain management in the treatment of Cancer.	Speaker: Dr. Rakesh Roy

19/06/2025	Topic: Journey from visible body to invisible energy.	Speaker: Ms. Payal Gupta Ms. Kavya Agarwal Ms Nishant Bhalotia
26/06/2025	Topic: Adcetris: Transforming front line treatment of Hodgkins Lymphoma	Speaker: Dr. Kaushik Paul
03/07/2025	Topic: Her2 Scoring and Interpretation in Her2 Low and Her2 Ultra Low Breast Cancer.	Speaker: Dr. Rakesh Roy Dr. Sunipa Ghosh
10/07/2025	Topic: Management of CUTI, HAP,VAP, present & future.	Speaker: Dr. Subhamoy Paul
17/07/2025	Panel Discussion Topic: Neuroendocrine tumors and the uses of Octreotide long sciting release as somatostatin inhibitor. Topic: ii) Training on Medical Records. (Online Programme)	Moderator :Dr. Rakesh Roy Chairperson: Dr. Arnab Gupta
24/07/2025	Topic: Role of Molecular Profiling in precision Oncology.	Ms. Yashodhara Bhattacharya (Product Manager & Sr.Genetic Counselor, 1 Cell .AI)
31/07/2025	Topic: Multidisciplinary Tumor Board	
07/08/2025	Topic: Parotid Maliganncy	Speaker: Dr. Mainak Chakraborty
14/08/2025	Topic: Harnesting nanoscale cellular communication for next-generation anticancer therapeutic.	Speaker: Dr. Tanmoy Saha
21/08/2025	Topic: Role of Radiation therapy in Non Small Cell Lung Cancer.	Speaker: Dr. Anwesh Mukherjee
28/08/2025	Topic: Pediatric Sarcoma	Speaker: Dr. Arnab Chakraborty

04/09/2025	Topic: i) Neo Adjuvant Chemotherapy Vs Chemoradiation in Esophagial Adeno Carcinoma.	Speaker: Dr. Prashant Sinha
11/09/2025	Topic : Journal Club	Speaker: Dr. Rupali Niraj Dr. Siddharth Khemka
18/09/2025	Topic: Cancer Prevention Through tobacco control, a public health priority for West Bengal . Panel Discussion : Saving mankind from hazards of tobacco.	Speaker : Dr. Nirmalya Mukherjee (Chief executive of public health research at MANT) Moderator : Dr. Arnab Gupta
25/09/2025	Topic: i) IO in Endometrial Cancer. Topic: ii) Targeted therapy in Ovarian Cancer.	Speaker: Dr. Chandrakant MV (Consultant Medical Oncologist, Naryana Hospital, Howrah) Speaker: Dr. Poulami Basu (Consultant Medical Oncologist, Netaji Subhas Bose Cancer Hospital)
09/10/2025	Topic: Fluid Cytology	Speaker : Dr. Sudopto Roy
16/10/2025	Topic: Management of GE Junction Cancers.	Speaker: Dr. Arnab Gupta Dr. Rupali Niraj
23/10/2025	Topic: Adaptive RT	Speaker: Dr. Sampuran Acharyya
30/10/2025	Topic: HPV Discuss Awareness	Speaker: Dr. Sandipan Chpwdhury

06/11/2025	Topic: PICC Line & Chemoport	Speaker : Dr. Shouptik Basu
13/11/2025	Topic: Surgical management for FAP-Familial Adenosis	Speaker: Moinak Chakraborty
20/11/2025	Topic: Recent recommendations on Cytology reporting.	Speaker: Dr. Sunipa Ghosh Pradhan Dr. Sagarika Dr. Soumendra Mishra
27/11/2025	Topic: Surgery for locally advanced Rectal Carcinoma- Whats new.	Speaker: Dr. Samir Bhattacharyya

Cancer Control Programme:

SL.NO.	DATE	PLACE	CO-ORGANISOR	TARGET	DOCTOR PRESENT
				POPULATION	
1	13.01.25	Salt Lake	Hariyana Vidyamandir School	Cancer Awareness	Dr. Arnab Gupta
2	21.01.25	Salt Lake	Heritage College	Cancer Awareness	Dr. Arnab Gupta
3	17.03.25	Tollygunge	NSHM, Siriti	Cancer Awareness	Dr. Suchhana Goswami Dr. Saswati Sorcar
4	26.04.25	Bolpur Municipality	Ganguly Health Care Bolpur Municipality	Cancer Awareness & Screening	Dr. Abhijit Sarkar Dr. Sandipan Choudhuri Dr. Souptik Basu Dr. Debdip Ganguly

5	02.05.25	Beliaghata	ICMR	Cancer Awareness	Dr. Indranil Chatterjee
			National Institute for	& Screening	
			Research in Bacterial		
			Infection, ID hospital		
6	14.06.25	Behala	Rotary Club of South	Cancer Awareness	Dr. Samir Bhattacharyya
			Calcutta		Dr. Arnab Gupta
					Dr. Sandipan Choudhuri
7	22.06.25	Baruipur	Rotary Club of	Cancer Awareness	Dr. Suchhanda Goswami
			Budge Budge		Dr. Saswati Sorcar
8	01.07.25	Shyamnagar	Bhatpara Municipality	Cancer Awareness	Dr. Abhijit Sarkar
				& CME	
9	02.08.25	Rashbehari	Kolkata Residents' Forum	Cancer Awareness	Dr. Souptik Basu
				& Screening	
10	23.08.25	Ruby, Kolkata	Rotary Club of South	Cancer Awareness	Dr. Indranil Chatterjee
			Calcutta		Dr. Souptik Basu
11	28.08.25	New Town	JIS Group, Woman Times	Cancer Awareness	Dr. Arnab Gupta
12	13.09.25	Chandannagar	Rotary Club of South	Cancer Awareness	Dr. Suchhanda Goswami
			Calcutta		Dr. Saswati Sorcar

13	14.09.25	Kolkata	Mahila Mondal	Cancer Awareness	Dr. Arnab Gupta
14	17.10.25	Kolkata	Asiatic Society	Cancer Awareness	Dr. Arnab Gupta
15	28.10.25	Kolkata	Khadhi Village Industry	Cancer Awareness	Dr. Abhijit Sarkar
			Commission		
16	17.11.25	Kolkata	Indian Oil Corporation	Cancer Awareness	Dr. Sandipan Chowdhury
			(Dhakuria)		

HPV VACCINATION ON Jan. 2025 to Dec. 2025

Date	Sponsor	No. of Vaccination
15.09.25	Lyness Club Srishti Mr. Kamal Kishan Chowdhury	10
15.11.25	Lyness Club Srishti Mr. Kamal Kishan Chowdhury	10
23.09.25	IWC Garden Reach	2
14.11.25	IWC Garden Reach	1
13.01.25	Individual Vaccination	30
to		
17.11.25		

Publications 2023 Onwards

Original work in form of presentation paper in various conferences.

Rana N S, Bhattacharjee G, Panda S. An observational study to assess local

control and neurocognitive functions after fractionated stereotactic radiosurgery for intracranial metastasis. An Abstract presented at AROICAN 2025.

Basu S. iCRS Alert: A novel predictive model and smartphone application utilizing Inflammatory Biomarkers to predict postoperative complications in Carcinoma Ovary patients undergoing Interval Cytoreductive Surgery and HIPEC. Scientific Proceeding of NATCON IASO Abstracts & Case reports 2025. Indian J Surg Oncol (2024). <https://doi.org/10.1007/s13193-024-02168-6>

Original work published in journals..

Sain B, Gupta A, Ghose A, Halder S, Bhattacharya S, Mondal R.R, Paul S, Are C, Boussios S. Impact of COVID-19 on cancer services and patients outcomes: a retrospective single-center study. Ann Transl Med 2023 1 <https://dx.doi.org/10.21037/atm-22-5876>

Sain B, Gupta A, Ghose A, Halder S, Mondal RR, Sen A.N, Saha B, Roy S; et al. Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre. J. Pers. Med. 2023,13,866. <https://doi.org/10.3390/jpm13050866>

D D Ghosh, R R Chowdhury, Dutta R, Mukhopadhyay I, Mukhopadhyay A, Roychoudhury S. In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries. <https://doi.org/10.1016/j.gore.2023.101209>

Haldar S, Saroj DK, Dixit A, Sarkar B, Yadav S. The Feasibility of Hybrid IMRT treatment planning for Left sided Chest Wall irradiation : A Comparative Treatment Planning Study. Iran J Med Phys 2023;20:31-41. [10.22308/IJMP.2022.60694.2022](https://doi.org/10.22308/IJMP.2022.60694.2022)

Haldar S, Dixit A, Sarkar B. Dosimetric Study of Hybrid Intensity Modulated Radiation Therapy Treatment Plan with Flattened Filter Free Photon Beam for Carcinoma of Breast: Treatment Planning Study. Turk J Oncol 2023;38(2):145-54 [doi:10.5505/tjo.2022.3783](https://doi.org/10.5505/tjo.2022.3783)

Haldar S, Sarkar B, Dixit A. Comparison of hybrid IMRT plans for breast cancer utilizing the variable ratio of 3DCRT and IMRT components to establish an optimal plan for target coverage with sparing lung and heart. [doi:10.22038/IJMP.2023.71357.2261](https://doi.org/10.22038/IJMP.2023.71357.2261)

Haldar S, Sarkar B, Dixit A. Dose To Organ At Risk And Its Characteristic Variation With The Clinically Used Different Prescription Levels For Early Stage Left Sided Breast Cancer.22 Nov 2023.<https://doi.org/10.1016.j.clon.2023.11.22>

Creutzberg, Carien L Barretina-Ginesta, Pilar et al Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup. The Lancet Oncology, Volume 25, Issue 9, 2024 e420 - e431.

McCormack M, Eminowicz G, D Gallardo, Diez P, Farrelly L, Kent C, Hudson E, Panades M, Mathew T, Anand A, Persic M, Forrest J, Bhana R, Reed N, Drake A, Adusumalli M, Mukhopadhyay A, King M, Whitmarsh K, McGrane J, Colombo N, Mak C, Mandal R, **Roy Chowdhury R**, Alamilla-Garcia A, Chávez-Blanco A, Feeney A, Vaja S, Hacker A M, Hackshaw A, Ledermann J A. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. The Lancet, Volume 404, Issue 10462, 1525 – 1535. 2024.11.14

Absar S, **Bhattacharyya S**, **Gupta A**. Cancer Trends in West Bengal Over 25 Years: A Comprehensive Single-Centre Study. Indian Journal of Surgical Oncology. <https://doi.org/10.1007/s13193-025-02252-5>. 2025.02.18

Sreenath Nihanthy D, Potharaju M, Chandrasekar S, Mangaleswaran B. Efficacy of CyberKnife Stereotactic Radiosurgery in Treating Trigeminal Neuralgia: A Single-Institution Study. DOI <https://doi.org/10.1055/s-0044-1801829>. ISSN 2277-954X. 2025 -04-02

Kushwaha N K, **Sreenath Nihanthy D**. From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma. DOI <https://doi.org/10.1200/OP-25-00198>. 2025.04.16

Gupta A, **Bhattacharyya S**, **Shaik A A**, **Khan M A**. Outcome of Level 111 Axillary Node Dissection in Breast Cancer: 20 years Single Unit Experience in a Comprehensive Cancer Centre in Eastern India. <https://doi.org/10.1007/s13193-025-02278-9>. 2025.03.21

Mondal R R, **Sahu S**, Haldar S, **Bhattacharyya S**, **Gupta A**. Risk factors for Positive Peritoneal Lavage Cytology in Stage I to III Colon Cancer: A Prospective Observational Study. Indian Journal of Surgical Oncology. 28 August 2025. <https://doi.org/10.1007/s13193-025-02416-3>.

Paul R, Sinharay S, Dhar D, Sarkar P, Chakraborty P, **Ghosh S**, Roy A, saha A, **Roychoudhury S**, Nath S. A signature of correlated CDC20 and UBCH10 expression indicates poor prognosis in primary head and neck squamous cell carcinoma. Paul et al. BMC Cancer (2025) 25:1458. <https://doi.org/10.1186/s12885-025-14773-x>

Sreenath Nihanthy D Sai Viksheth Raj, Mahadev P), et al. The Integration of Artificial Intelligence (AI) in Oncology: Transforming Cancer Care. Int J Spine Surg Res. 2025; 1(2): 1-6

Rastogi S, **Sreenath Nihanthy D**. Where the Borders Bleed: Festivals, Fragility, and the Footfall of a Young Soldier's Return. NJCO Global Oncology, August 2025. DOI <https://doi.org/10.1200/GO-25-00239>

Sreenath Nihanthy D, pandalanghai S, Kapoor A, Govind R, Kausik M. R, Nair R, Bhuvana D, Rathore A, Kumar M, and Mulajkar D. A comparative analysis of palbociclib and Ribociclib in metastatic hormone receptor –positive, HER2-Negative breast cancer: a prospective mid term follow –up study from an Indian cohort. BMC Cancer- August 2025.

Sreenath Nihanthy D, Kushwaha N K, Kaushik M R, Govind Rajath. Optimizing Oncological Care in Patients with End-stage Chronic Kidney Disease on Dialysis: Indian Scenario. Ind J Med Paediatr Oncol. February 2025

Santhosh A, **Sreenath Nihanthy D**. Treatments for unresectable hepatocellular carcinoma: insight from CheckMate9DW. The Lancet- November 2025.

Sreenath Nihanthy D. A Good Innings – A Tale of Hope, Heartbreak, and Healing. N ENGL J MED 392;17 NEJM.ORG May 1, 2025

Santosh A, **Sreenath Nihanthy D**. Checkpoint Dilemma: KEYNOTE -564's Triumph Amidst the Failures of Its Rivals in Renal Cell Carcinoma. J Case Rep Rev Med .2025; 1(4):1-2 .doi :<https://doi.org/10.64978/jcrrm-0115>.

Sreejith B R, Gupta P, Pothina S H, Kushwaha N K, Sarkar N, **Sreenath Nihanthy D**. Gastrointestinal Stromal Tumours : Epitome of Variability. 18 November 2025. SN Comprehensive Clinical Medicine .

Basu S. AI-Predict- BM: Artificial Intelligence to predict respectability and evaluate decisions for induction chemotherapy in treatment of buccal mucosa cancer.- A novel pilot study. Natl J Maxillofac Surg. 2025 May-Aug; 16(2):256-262. doi: 10.4103/njms.njms_195_24

Original work in form of poster presentation

Mukhopadhyay A, Ghosh T, Bhattacharjee D, Chakraborty D, Gupta , **Roy Chowdhury R**, Chatterjee P, Vemekar M, Chowdhury RR, Intermittent PARP Inhibitor Regimen In Ovarian Cancer (IPIROC): Origin and Feasibility Of Implementing A Proof –Of –Concept Exploratory Study.18 October 2023 Abstracts.

Asima Mukhopadhyay, TanushriGhosh, DaityBhattacharjee, DonaChakraborty, Rama Gupta, Indrani Roychowdhury, Puja Chatterjee, Manisha Vernekar, **Roy Chowdhury R**, Intermittent PARP inhibitor regimen in ovarian cancer (IPIROC): origin and feasibility of implementing a proof-of-concept exploratory study. and Ipiroc Study Group.7 November 2023

Ph.D/ MD/ DNB/ MSc Thesis / Dissertation.

Year	Name of DNB Candidate	Thesis Topic	Guide/ Co-Guide
2020	Dr. Vishal Mukherjee	Pathological Complete Response After Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer Subtypes – A Prospective Observational Study.	Prof. (Dr.) Arnab Gupta, / Prof. (Dr.) Saradindu Ghosh
	Dr. Radha Raman Mondal	Peritoneal Lavage Cytology in Colon Cancer: Association with Pathological Stage & Laterality – A Prospective Observational Study	Prof. (Dr.) Samir Bhattacharyya /Dr. Subrata Kumar Sahu,

2021	Dr. Pranjit Kalita	Histopathological Regression Grade After Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer Subtypes- A Prospective Observational Study	Dr. Subrata Kumar Sahu
2021	Dr. Azam Ali Shaik	Comparison On Lymph Node Positivity In Patients Receiving Neoadjuvant Chemotherapy Vs Upfront Surgery In Resectable Stage 3 And Stage 4 Oral Cavity Cancers:An Observational Study	Dr. Arnab Gupta
	Dr. Pratap Kumar Deb	A PROSPECTIVE OBSERVATIONAL STUDY OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY OF CARCINOMA STOMACH WITH RESPECT TO PRESENCE OR ABSENCE OF HER 2 OVEREXPRESSION	Dr. Samir Bhattacharyya
	Dr. Indrajit Malik	Pathological T staging and N staging relation in Gall Bladder Carcinoma and its relation to clinical outcome	Dr. Arnab Gupta
2022	Dr. Sushanta Sarkar	Comparison of Surgical and Histopathological Margins of Upfront Operable Oral Squamous Cell Carcinoma: An Observational Study	Dr. Saradindu Ghosh

	Dr. Tapas Ranjan Behera	Association of Body mass Index with Clinicopathological characteristics and Hormone Receptor status in Breast Cancer patients: A prospective observational study.	Dr. Arnab Gupta
	Dr. Piyas Sengupta	Correlation of Msi Status With Response To Neoadjuvant Chemoradiation in Locally Advanced Rectal Adenocarcinoma	Dr. Samir Bhattacharyya
2022	Dr. Khan Maaz Ahmed Wasim Ahmed	“A Comparative Prospective, Observational Study Of Short Term Outcomes of Laparoscopic Versus Open Surgery For Colorectal Cancer”	Dr. Subrata Kumar Sahu
2023	Dr. Namrata Majumdar	Correlation of HER 2 NEU Positivity and Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Carcinoma.	Dr. Samir Bhattacharyya
	Dr. Prashant Kumar Sinha	Comparative Study of Response of Induction Chemotherapy between Locally Advanced Tongue and Gingivobuccal Squamous cell carcinoma.	Dr. Saradindu Ghosh
	Dr. Subrato Mahakur	Clinico-Pathological Response evaluation of Single (ER or PR) versus Double (ER and PR) Hormone receptor positive Her-2 negative breast Cancer patients treated with Neoadjuvant chemotherapy	Dr. Arnab Gupta

	Dr. Siddharth	Comparative Analysis of Short-Term Surgical Outcomes: Proximal Gastrectomy vs. Total Gastrectomy for Proximal Gastric Adenocarcinoma.	Dr. Subrata Kumar Sahu
2024	Dr. Bajrang Sharma	Correlation Of Nutritional And Inflammatory Markers In Predicting Post-Operative Complications In Major Gi Cancer Surgeries	Dr. Subrata Kumar
	Dr. Jaydeep Mandal	Evaluation of Indocyanine Green (ICG), Blue Dye, and Combined Method in Sentinel Lymph Node Biopsy for Early Breast Carcinoma	Prof. (Dr.) Samir Bhattacharyya
	Dr. Himen Baidya	Comparative Analysis of Lymph Node Metastasis in Gingivobuccal Sulcus versus Tongue Squamous Cell Carcinoma: A Clinicopathological Study	Dr. Saradindu Ghosh
	Dr. Rupali Niraj	Safety And Morbidity Analysis Of Level Iii Axillary Lymph Node Dissection In Breast Cancer - An Ambispective Study	Prof. (Dr.) Arnab Gupta

Case presentations published in Journals

Deb P K, Roy R, Roy S, Roy S. Epitheloid hemangioendothelioma of the urinary bladder: A case report of a rare entity. Indian J Case Reports 2023;April 05 (Epub ahead of print).

Deb P K, Roy R, Roy S, Roy S. HCC masquerading as gluteal mass. A rare presentation. Indian J Case Reports 2023;March 27 (Epub ahead of print).

Sain B, Gupta A, Ghose A, Halder S, Mukherjee V, Bhattacharya S, Mondal RR, Sen A.N, Saha B, Roy S; et al. Clinico-Pathological Factors determining Recurrence of Phyllodes tumors of the Breast: the 25-Year Experience at a Tertiary Cancer Centre. J.Pers.Med.2023,13,866 <https://doi.org/10.3390/jpm13050866>

Sahu S K , Deb P K, Bhattacharyya S, Gupta A. Superior mesenteric artery syndrome post-total proctocolectomy: A challenging post-operative dilemma. Indian J Case Reports 2023:October 29

Kalita P. Gupta A, Sengupta P, Bhattacharyya S, Mishra S, Dasgupta S. Carcinoma of the axillary tail of Spence: A rare case report.
<https://doi.org/10.1016/j.ijscr.2023.109151>

Kalita P. Gupta A, Sengupta P, Bhattacharyya S. A rare presentation of jejuna GIST: A case report. Indian J Case Reports. 2024;December 29 (Epub ahead of print)

Deb PK, Sahu SK, Bhattacharyya S, Behera T. Appendicular schwannoma: Case report of a rare differential of a right iliac fossa mass. Indian J Case Reports. 2024.July 08 (Epub ahead of print)

Book Chapter

Meyur S."Chronic Lymphocytic Leukemia" in IACM Clinical Medicine Update 2025 .Jaypee Publishers.

